Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharming GroupPHAR -1.66%76 3-Year Share Buyback Ratio is -2.30 as of Jun. 2026. GuruFocus rates PHAR with a GF Score™ of 76/100 and a GF Value™ of $13.70 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,189 Biotechnology companies, Pharming Group ranks better than 76.2% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Pharming Group's current 3-Year Share Buyback Ratio was -2.30%.
The historical rank and industry rank for Pharming Group's 3-Year Share Buyback Ratio or its related term are showing as below:
PHAR'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -99.9 Med: -11.8 Max: -1.3
Current: -2.3
During the past 13 years, Pharming Group's highest 3-Year Share Buyback Ratio was -1.30%. The lowest was -99.90%. And the median was -11.80%.
PHAR's 3-Year Share Buyback Ratio is ranked better than 76.2% of 1189
companies
in the Biotechnology industry
Industry Median: -11.8
vs PHAR: -2.30
Pharming Group (NAS:PHAR) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Pharming Group 3-Year Share Buyback Ratio Related Terms
PHAR vs VRTX, REGN, MRNA: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Pharming Group's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharming Group 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharming Group's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Pharming Group's 3-Year Share Buyback Ratio falls into.
Pharming Group 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -2.30 mean?
Pharming Group (PHAR) has a 3-Year Share Buyback Ratio of -2.30 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Pharming Group and its competitors. According to the industry distribution chart, Pharming Group ranks #283 out of 1189 companies in the Biotechnology industry, placing it in the top 23.8%.
Is Pharming Group's 3-Year Share Buyback Ratio too high?
Pharming Group's current 3-Year Share Buyback Ratio is -2.30. Based on the distribution chart, Pharming Group ranks #283 out of 1189 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharming Group has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #283 out of 1189 companies for 3-Year Share Buyback Ratio. This places Pharming Group in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Pharming Group and its competitors. Pharming Group's current 3-Year Share Buyback Ratio is -2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.70, compared to a current price of $11.54 — trading 15.8% below its estimated fair value. The current 3-Year Share Buyback Ratio is -2.30. Pharming Group's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Pharming Group (PHAR), the current 3-Year Share Buyback Ratio is -2.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of $11.54 is trading 15.8% below its estimated GF Value™ of $13.70.
GuruFocus considers Pharming Group to be Modestly Undervalued.
Key valuation signals for PHAR:
3-Year Share Buyback Ratio: -2.30
GF Value™: $13.70 vs. price of $11.54 (15.8% below fair value)
No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
76GF Score
Get the complete analysis for PHAR
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAR has been successfully added to your 
